Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Gastrointestinal 1

Conditions

Stomach Neoplasms 24Colorectal Neoplasms 12Colonic Neoplasms 9Rectal Neoplasms 6Carcinoma, Hepatocellular 6Pancreatic Neoplasms 5Esophageal Squamous Cell Carcinoma 4Carcinoma, Non-Small-Cell Lung 4Breast Neoplasms 4Biliary Tract Neoplasms 4Unspecified Adult Solid Tumor, Protocol Specific 3Squamous Cell Carcinoma of Head and Neck 3Head and Neck Neoplasms 3Gallbladder Neoplasms 3Esophageal Neoplasms 3HER2-positive Gastric Cancer 2Cholangiocarcinoma 2Uterine Cervical Neoplasms 1Stage IA Pancreatic Adenocarcinoma 1Solid Tumor 1Recurrence 1Nasopharyngeal Carcinoma 1Mouth Neoplasms 1Malignant Neoplasms of Digestive Organs 1Lung Neoplasms 1Klatskin Tumor 1Immunotherapy 1Gastric Adenocarcinoma 1Fruquintinib 1For Patients With Colorectal Cancer Liver Metastases Who Were Not Able to Curative Surgical Resection.Focused on the Treatment Effect With the Quintuple Method 1

Interventions

pembrolizumab 92Gemcitabine 56Nivolumab 50Cisplatin 39atezolizumab 37Carboplatin 30avelumab 29enfortumab vedotin 26Docetaxel 23Magnetic Resonance Spectroscopy 19Mitomycin 17Ipilimumab 17Paclitaxel 16Specimen Handling 14durvalumab 11toripalimab 10sacituzumab govitecan 10Pemetrexed 10cabozantinib 9Taxes 8vinflunine 7Cyclophosphamide 7tislelizumab 6Injections 6Bevacizumab 6pemigatinib 5fludarabine 5disitamab vedotin 5Standard of Care 5Radiosurgery 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Transitional Cell × Tegafur × Clear all
NCT05867121 2026-04-27

A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010

Genentech, Inc.

Phase 1 Active not recruiting
102 enrolled
GastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡